{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:52:19Z","timestamp":1789501939253,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00228-015-1896-x","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T04:25:28Z","timestamp":1436243128000},"page":"1067-1073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy"],"prefix":"10.1007","volume":"71","author":[{"given":"Paulo Roberto Xavier","family":"Tomaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Rocha","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline Scholz","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia Ogawa","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Viviane","family":"Gaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eduardo","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Costa","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Caleb J\u00fanior Lima","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"key":"1896_CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.socscimed.2014.11.054","volume":"124C","author":"H Hiilamo","year":"2015","unstructured":"Hiilamo H, Glantz SA (2015) Implementation of effective cigarette health warning labels among low and middle income countries: state capacity, path-dependency and tobacco industry activity. Soc Sci Med 124C:241\u2013245","journal-title":"Soc Sci Med"},{"key":"1896_CR2","doi-asserted-by":"crossref","unstructured":"Tomioka H, Sekiya R, Nishio C, Ishimoto G. Impact of smoking cessation therapy on health-related quality of life. BMJ Open Respir Res 2014;1:e000047.","DOI":"10.1136\/bmjresp-2014-000047"},{"key":"1896_CR3","doi-asserted-by":"crossref","unstructured":"A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008;35:158-176.","DOI":"10.1016\/j.amepre.2008.04.009"},{"key":"1896_CR4","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/add.12172","volume":"108","author":"H Pine-Abata","year":"2013","unstructured":"Pine-Abata H, McNeill A, Murray R, Bitton A, Rigotti N, Raw M (2013) A survey of tobacco dependence treatment services in 121 countries. Addiction 108:1476\u20131484","journal-title":"Addiction"},{"key":"1896_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1360-0443.2012.04009.x","volume":"108","author":"KA Kasza","year":"2013","unstructured":"Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV, et al. (2013) Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) four country survey. Addiction 108:193\u2013202","journal-title":"Addiction"},{"key":"1896_CR6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","volume":"296","author":"DE Jorenby","year":"2006","unstructured":"Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56\u201363","journal-title":"JAMA"},{"key":"1896_CR7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jama.2014.7195","volume":"312","author":"CF Koegelenberg","year":"2014","unstructured":"Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O\u2019Brien JA, et al. (2014) Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 312:155\u2013161","journal-title":"JAMA"},{"key":"1896_CR8","first-page":"680","volume":"63","author":"E Espanol","year":"2014","unstructured":"Espanol E, Kelsberg G, Safranek S (2014) Clinical inquiry: does any antidepressant besides bupropion help smokers quit? J Fam Pract 63:680\u2013688","journal-title":"J Fam Pract"},{"key":"1896_CR9","doi-asserted-by":"crossref","unstructured":"Verde Z, Santiago C, Rodriguez Gonzalez-Moro JM, de Lucas Ramos P, Lopez Martin S, Bandres F, et al. \u2018Smoking genes\u2019: a genetic association study. PLoS One 2011;6:e26668.","DOI":"10.1371\/journal.pone.0026668"},{"key":"1896_CR10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1375\/twin.9.1.64","volume":"9","author":"U Broms","year":"2006","unstructured":"Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J (2006) Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res Hum Genet 9:64\u201372","journal-title":"Twin Res Hum Genet"},{"key":"1896_CR11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1017\/S0033291703001582","volume":"34","author":"CN Lessov","year":"2004","unstructured":"Lessov CN, Martin NG, Statham DJ, Todorov AA, Slutske WS, Bucholz KK, et al. (2004) Defining nicotine dependence for genetic research: evidence from Australian twins. Psychol Med 34:865\u2013879","journal-title":"Psychol Med"},{"key":"1896_CR12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/hmg\/ddl441","volume":"16","author":"LJ Bierut","year":"2007","unstructured":"Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, et al. (2007) Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16:24\u201335","journal-title":"Hum Mol Genet"},{"key":"1896_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/hmg\/ddl438","volume":"16","author":"SF Saccone","year":"2007","unstructured":"Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al. (2007) Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16:36\u201349","journal-title":"Hum Mol Genet"},{"key":"1896_CR14","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2007.09.006","volume":"33","author":"CE Lerman","year":"2007","unstructured":"Lerman CE, Schnoll RA, Munafo MR (2007) Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 33:S398\u2013S405","journal-title":"Am J Prev Med"},{"key":"1896_CR15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/1462220031000073667","volume":"5","author":"H Xian","year":"2003","unstructured":"Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M, True WR, et al. (2003) The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res 5:245\u2013254","journal-title":"Nicotine Tob Res"},{"key":"1896_CR16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00008571-200211000-00007","volume":"12","author":"C Lerman","year":"2002","unstructured":"Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, et al. (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12:627\u2013634","journal-title":"Pharmacogenetics"},{"key":"1896_CR17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/14622200701382033","volume":"9","author":"SP David","year":"2007","unstructured":"David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, et al. (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9:821\u2013833","journal-title":"Nicotine Tob Res"},{"key":"1896_CR18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/1462220031000094123","volume":"5","author":"SP David","year":"2003","unstructured":"David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, et al. (2003) Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 5:935\u2013942","journal-title":"Nicotine Tob Res"},{"key":"1896_CR19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/YPG.0b013e3282df0939","volume":"18","author":"DH Han","year":"2008","unstructured":"Han DH, Joe KH, Na C, Lee YS (2008) Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatr Genet 18:11\u201316","journal-title":"Psychiatr Genet"},{"key":"1896_CR20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0920-9964(03)00220-2","volume":"67","author":"C Dubertret","year":"2004","unstructured":"Dubertret C, Gouya L, Hanoun N, Deybach JC, Ades J, Hamon M, et al. (2004) The 3\u2032 region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr Res 67:75\u201385","journal-title":"Schizophr Res"},{"key":"1896_CR21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/humu.20039","volume":"23","author":"MJ Neville","year":"2004","unstructured":"Neville MJ, Johnstone EC, Walton RT (2004) Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 23:540\u2013545","journal-title":"Hum Mutat"},{"key":"1896_CR22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1472-8206.2009.00753.x","volume":"24","author":"I Arenaz","year":"2010","unstructured":"Arenaz I, Vicente J, Fanlo A, Vasquez P, Medina JC, Conde B, et al. (2010) Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans. Fundam Clin Pharmacol 24:247\u2013253","journal-title":"Fundam Clin Pharmacol"},{"key":"1896_CR23","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ntr\/nts230","volume":"15","author":"JS Issa","year":"2013","unstructured":"Issa JS, Abe TO, Moura S, Santos PC, Pereira AC (2013) Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nicotine Tob Res 15:1146\u20131150","journal-title":"Nicotine Tob Res"},{"key":"1896_CR24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijcard.2014.01.055","volume":"172","author":"JS Issa","year":"2014","unstructured":"Issa JS, Santos PC, Vieira LP, Abe TO, Kuperszmidt CS, Nakasato M, et al. (2014) Smoking cessation and weight gain in patients with cardiovascular disease or risk factor. Int J Cardiol 172:485\u2013487","journal-title":"Int J Cardiol"},{"key":"1896_CR25","first-page":"763","volume":"69","author":"KO Fagerstrom","year":"1990","unstructured":"Fagerstrom KO, Heatherton TF, Kozlowski LT (1990) Nicotine addiction and its assessment. Ear Nose Throat J 69:763\u2013765","journal-title":"Ear Nose Throat J"},{"key":"1896_CR26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2350-12-13","volume":"12","author":"PC Santos","year":"2011","unstructured":"Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, et al. (2011) CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 12:13","journal-title":"BMC Med Genet"},{"key":"1896_CR27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1471-2350-12-136","volume":"12","author":"PC Santos","year":"2011","unstructured":"Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, et al. (2011) SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 12:136","journal-title":"BMC Med Genet"},{"key":"1896_CR28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","volume":"11","author":"T Lang","year":"2001","unstructured":"Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, et al. (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399\u2013415","journal-title":"Pharmacogenetics"},{"key":"1896_CR29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/jpet.111.183111","volume":"338","author":"H Zhang","year":"2011","unstructured":"Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF (2011) Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J Pharmacol Exp Ther 338:803\u2013809","journal-title":"J Pharmacol Exp Ther"},{"key":"1896_CR30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1037\/0278-6133.22.5.541","volume":"22","author":"C Lerman","year":"2003","unstructured":"Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk Jr. LH, Pinto A, et al. (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541\u2013548","journal-title":"Health Psychol"},{"key":"1896_CR31","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","volume":"28","author":"LM Hesse","year":"2000","unstructured":"Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, et al. (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176\u20131183","journal-title":"Drug Metab Dispos"},{"key":"1896_CR32","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12054-8","volume":"28","author":"SR Faucette","year":"2000","unstructured":"Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, et al. (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222\u20131230","journal-title":"Drug Metab Dispos"},{"key":"1896_CR33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","volume":"4","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Klein K (2013) Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 4:24","journal-title":"Front Genet"},{"key":"1896_CR34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008571-200310000-00005","volume":"13","author":"J Kirchheiner","year":"2003","unstructured":"Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, et al. (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619\u2013626","journal-title":"Pharmacogenetics"},{"key":"1896_CR35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/clpt.2012.186","volume":"92","author":"AZ Zhu","year":"2012","unstructured":"Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. (2012) CYP2B6 and bupropion\u2019s smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther 92:771\u2013777","journal-title":"Clin Pharmacol Ther"},{"key":"1896_CR36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.pharmtox.48.113006.094753","volume":"48","author":"A Telenti","year":"2008","unstructured":"Telenti A, Zanger UM (2008) Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 48:227\u2013256","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1896_CR37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","volume":"6","author":"NY Rakhmanina","year":"2010","unstructured":"Rakhmanina NY, van den Anker JN (2010) Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 6:95\u2013103","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1896_CR38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","volume":"325","author":"MH Hofmann","year":"2008","unstructured":"Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, et al. (2008) Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325:284\u2013292","journal-title":"J Pharmacol Exp Ther"},{"key":"1896_CR39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","volume":"64","author":"C Nyakutira","year":"2008","unstructured":"Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. (2008) High prevalence of the CYP2B6 516G\u2013>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64:357\u2013365","journal-title":"Eur J Clin Pharmacol"},{"key":"1896_CR40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008571-200404000-00002","volume":"14","author":"LM Hesse","year":"2004","unstructured":"Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, et al. (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225\u2013238","journal-title":"Pharmacogenetics"},{"key":"1896_CR41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/(SICI)1096-8628(20000214)90:4<299::AID-AJMG7>3.0.CO;2-Y","volume":"90","author":"LJ Bierut","year":"2000","unstructured":"Bierut LJ, Rice JP, Edenberg HJ, Goate A, Foroud T, Cloninger CR, et al. (2000) Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 90:299\u2013302","journal-title":"Am J Med Genet"},{"key":"1896_CR42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00008571-199804000-00005","volume":"8","author":"AB Singleton","year":"1998","unstructured":"Singleton AB, Thomson JH, Morris CM, Court JA, Lloyd S, Cholerton S (1998) Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 8:125\u2013128","journal-title":"Pharmacogenetics"},{"key":"1896_CR43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1369-1600.2004.tb00536.x","volume":"9","author":"EC Johnstone","year":"2004","unstructured":"Johnstone EC, Yudkin P, Griffiths SE, Fuller A, Murphy M, Walton R (2004) The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population. Addict Biol 9:221\u2013226","journal-title":"Addict Biol"},{"key":"1896_CR44","doi-asserted-by":"crossref","unstructured":"Riccardi LN, Carano F, Bini C, Ceccardi S, Ferri G, Pelotti S. CYP2B6 gene single-nucleotide polymorphisms in an Italian population sample and relationship with nicotine dependence. Genet Test Mol Biomarkers; 2015.","DOI":"10.1089\/gtmb.2014.0239"},{"key":"1896_CR45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/sj.tpj.6500227","volume":"4","author":"J Erblich","year":"2004","unstructured":"Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH (2004) Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J 4:102\u2013109","journal-title":"Pharmacogenomics J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1896-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1896-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1896-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T02:00:13Z","timestamp":1748484013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1896-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1896"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1896-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,8]]}}}